期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 523, 期 1, 页码 398-409出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2017.03.052
关键词
Thymoquinone; PEGylated liposomes; Radioprotection; Supercritical anti-solvent process; In-vivo; Pharmacokinetics
资金
- University Grants Commission, New Delhi, India under the Special Assistant Program (SAP-II) [F. 3-58/2011]
The aim of this study was to develop Thymoquinone (TQ) loaded PEGylated liposomes using supercritical anti-solvent (SAS) process for enhanced blood circulation, and greater radioprotection. The SAS process of PEGylated liposomes synthesis was optimized by Box-Behnken design. Spherical liposomes with a particle size of 195.6 +/- 5.56 nm and entrapment efficiency (%EE) of 89.4 +/- 3.69% were obtained. Optimized SAS process parameters; temperature, pressure and solution flow rate were 35 degrees C,140 bar and 0.18 mL/min, respectively, while 7.5 mmol phospholipid, 0.75 mmol of cholesterol, and 1 mmol TQ were optimized formulation ingredients. Incorporation of MPEG-2000-DSPE (5% w/w) provided the PEGylated liposomes (FV-17B; particle size = 231.3 +/- 6.74 nm, %EE = 91.9 +/- 3.45%, maximum TQ release >70% in 24 h). Pharmacokinetics of FV-17B in mice demonstrated distinctly superior systemic circulation time for TQ in plasma. Effectiveness of radioprotection by FV-17B in mice model was demonstrated by non -significant body weight change, normal vital blood components (WBCs, RBCs, and Platelets), micronuclei and spleen index and increased survival probability in post irradiation animal group as compared to controls (plain TQ and marketed formulation). Altogether, the results anticipated that the SAS process could serve as a single step environmental friendly technique for the development of stable long circulating TQ loaded liposomes for effective radioprotection. (C) 2017 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据